Use of ErbB3 inhibitors in the treatment of triple negative and basal-like breast cancers
AssigneeMerrimack Pharmaceuticals, Inc.
InventorsVictor Moyo, Gabriela Garcia
Life of this patent
Estimating the term…
Abstract
Provided are methods of suppressing growth of triple negative breast tumors and basal-like breast tumors by contacting tumor cells with an ErbB3 inhibitor, e.g., an anti-ErbB3 antibody. Also provided are methods for treating triple negative breast cancer or basal-like breast cancer in a patient by administering to the patient an ErbB3 inhibitor, e.g., an anti-ErbB3 antibody. The treatment methods can further comprise selecting a patient having a triple negative breast cancer or basal-like breast cancer and then administering an ErbB3 inhibitor to the patient. The treatment methods also can further comprise administering at least one additional anti-cancer agent to the patient in combination with the ErbB3 inhibitor.
Claims20
A method of treating triple negative breast cancer which expresses ErbB3, the method comprising:
- identifying a patient with a triple negative breast cancer tumor, and
- administering to the identified patient an effective amount of an anti-cancer agent comprising an anti-ErbB3 antibody that comprises, in amino terminal to carboxy terminal order, a VH CDR1 sequence as shown in SEQ ID NO:3, a VH CDR2 sequence as shown in SEQ ID NO:4 and a VH CDR3 sequence as shown in SEQ ID NO:5, and, in amino terminal to carboxy terminal order, a VL CDR1 sequence as shown in SEQ ID NO:6, a VL CDR2 sequence as shown in SEQ ID NO:7 and a VL CDR3 sequence as shown in SEQ ID NO:8.
A method of treating triple negative breast cancer which expresses ErbB3, the method comprising:
- identifying a patient with a basal-like breast cancer tumor;
- and
- administering to the identified patient an effective amount of an anti-cancer agent comprising an anti-ErbB3 antibody that comprises, in amino terminal to carboxy terminal order, a VH CDR1 sequence as shown in SEQ ID NO:3, a VH CDR2 sequence as shown in SEQ ID NO:4 and a VH CDR3 sequence as shown in SEQ ID NO:5, and, in amino terminal to carboxy terminal order, a VL CDR1 sequence as shown in SEQ ID NO:6, a VL CDR2 sequence as shown in SEQ ID NO:7 and a VL CDR3 sequence as shown in SEQ ID NO:8.
Dependencies are inferred from the claim text.